PER-022-10已完成未知
Effects of 150 mcg Aleglitazar on Renal Function in Patients With Type 2 Diabetes and Moderate Renal Impairment, as Compared to Actos®
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 80（—）
入选标准
- •Age> 18 years in the selection visit.
- •Men and women diagnosed with DM2 based on the WHO criteria for at least 1 month before the selection visit.
- •3 Never before receiving the drug or being treated with either monotherapy or a combination therapy of antihyperglycemic drugs (stably for> 1 month in the selection visit, no more than two combined treatments).
- •HbA1c of 6.5 -10.0% (inclusive) in the selection visit.
- •Fasting plasma glucose (fasting plasma glucose. FPG) <240 mg / dl (13.3 mmol / L) at the selection visit.
- •cGFRmdrd> 30 and <60 ml / min / 1.73 m2 in the selection visit
- •UACR <3000 ug / mg at the visit of choice.
- •A body mass index from 25.0 kg / m2 (Asian patients; from 23.0 kg / m2) to 35.0 kg / m2.
- •Be able and willing to provide written informed consent and comply with the requirements of the study protocol
排除标准
- •Previous or current treatment with a thiazolidinedione (eg, medications containing pioglitazone or rosiglitazone such as Actos®, Avandia®, ActoplusMet Avaudamet® or Avandary, another receptor agonist activated by peroxisomal proliferators (peroxisome proliferatoractivated receptor, PPAR) or a PPAR a / y dual agonist,
- •Previous or current insulin treatment (with the exception of emergency cases in which insulin is administered for <7 consecutive days),
- •Treatment with fibrates in the 3 months prior to the selection visit.
- •Treatment with statins in the last month before selection, except in a STABLE manner and that requires unlikely changes during the study.
- •Treatment with medications that interfere with the measurement of creatinine (eg, cimetidine, trimethoprim, probenecid, siilfonaraides, procaine or lysoolsulfones).
- •Chronic therapy with NSAID (except for prophylactic low-dose aspirin in a stable manner in the last month before selection: dose not exceeding 100 mg daily; paracetamol or acetaminophen is allowed).
- •Antihypertensive therapy in the last 3 months before the selection, except in a STABLE manner and which unlikely to require changes during the study.
- •Known diagnosis of kidney disease other than diabetic nephropathy (eg, polycystic kidney disease, kidney transplant, kidney cancer).
- •Systemic corticosteroid therapy within 3 months prior to the selection visit,
- •Uncontrolled hypertension (PAS> 140 mm Hg and / or PAD> 90 mm Hg despite therapy with an antihypertensive drug; mean of two measurements) at the selection visit.
- •11. Impaired liver function (TGP or TGO> 3 times above the upper limit of the normal range [upper limit of normal, ULN]) at the selection visit.
- •Creatine phosphokinase (creatine phosphokinase, CPK)> 3 times on the ULN in the selection visit.
- •History of drug-induced myopathy.
- •Hemoglobin <11 g / dl at the selection visit [continuous treatment with erythropoiesis stimulating agents] is allowed.
- •Congestive heart failure classified as functional class II to IV according to the criteria of the New York Heart Association (NYHA) on or before the selection or randomization visit.
- •Peripheral edema above the ankle level in the selection or randomization visit.
- •Myocardial infarction, acute coronary syndrome or transient ischemic stroke / stroke within 6 months prior to selection.
- •Vascular or cardiac surgery within 6 months prior to the selection visit.
- •Known macular edema on or before the selection visit.
- •Major surgery scheduled to be performed during the course of the study.
- •Any serious illness (such as metastatic cancer. Major active infection, severe psychiatric disorder) at the screening visit.
- •Any other significant medical condition that does not allow patient participation in this investigative study.
- •Positive pregnancy test, lactating women and those who are not using an appropriate contraceptive method.
- •Participation in any clinical study with an investigational drug within three months prior to the selection view.
研究者
相似试验
进行中（未招募）
不适用
Effects of 150 µg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos. - NDEUCTR2009-012270-12-ITF. Hoffmann - La Roche Ltd.300
进行中（未招募）
不适用
Effects of 150 µg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos®Type 2 diabetes with moderate renal function impairmentMedDRA version: 12.0Level: LLTClassification code 10007649Term: Cardiovascular disorderEUCTR2009-012270-12-HUF. Hoffmann-La Roche Ltd.300
进行中（未招募）
不适用
Effects of 150 µg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos®Type 2 diabetes with moderate renal function impairmentMedDRA version: 12.0Level: LLTClassification code 10007649Term: Cardiovascular disorderEUCTR2009-012270-12-DEF. Hoffmann-La Roche Ltd.300
进行中（未招募）
不适用
Effects of 150 µg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos®Type 2 diabetes with moderate renal function impairmentMedDRA version: 12.0Level: LLTClassification code 10007649Term: Cardiovascular disorderEUCTR2009-012270-12-SKF. Hoffmann-La Roche Ltd.300
已完成
2 期
A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal ImpairmentDiabetes Mellitus Type 2NCT01043029Hoffmann-La Roche302